462 related articles for article (PubMed ID: 22821599)
1. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
4. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance.
Saito H; Hirano H; Ishikawa T
Mini Rev Med Chem; 2007 Oct; 7(10):1009-18. PubMed ID: 17979803
[TBL] [Abstract][Full Text] [Related]
5. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
6. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
7. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
9. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
10. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
11. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
[TBL] [Abstract][Full Text] [Related]
12. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
13. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
14. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Ishikawa T; Nakagawa H
J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
[TBL] [Abstract][Full Text] [Related]
15. BCRP/ABCG2 inhibitors: a patent review (2009-present).
Wiese M
Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
[TBL] [Abstract][Full Text] [Related]
16. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
17. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Modok S; Mellor HR; Callaghan R
Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2.
Ishikawa T; Hirano H; Saito H; Sano K; Ikegami Y; Yamaotsu N; Hirono S
Mini Rev Med Chem; 2012 Jun; 12(6):505-14. PubMed ID: 22587765
[TBL] [Abstract][Full Text] [Related]
19. 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
Stefan K; Schmitt SM; Wiese M
J Med Chem; 2017 Nov; 60(21):8758-8780. PubMed ID: 29016119
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]